AMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
AMARIN CORP PLC\UK
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$11.53+0.21 (+1.86%)
Close on Oct 19, 2026
- Market cap
- $4.80B
- P/E (TTM)
- –
- Dividend yield
- –
AMARIN CORP PLC\UK revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue, Net | $39.08M | $43.33M | $46.54M | $48.56M | $46.62M | $41.04M | $60.07M | $41.85M | $47.51M | $55.16M | $70.56M | $64.90M | 92.6% | -16.2% |
| Licensing and Royalty Revenue | $3.13M | $1.81M | $2.68M | $1.11M | $26.12M | $982.00K | $2.24M | $446.00K | $19.98M | $1.36M | $4.16M | $1.15M | 7.4% | -88.0% |
By region
From the segment and revenue-disaggregation notes of Amarin Corp Plc\Uk's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.